Page last updated: 2024-08-16

trimipramine and sirolimus

trimipramine has been researched along with sirolimus in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Ciszek, R; Ekolle Ndode-Ekane, X; Hämäläinen, E; Hiltunen, M; Hujo, M; Kansanen, E; Levonen, AL; Lipponen, A; Natunen, T; Paananen, J; Pitkänen, A; Poulsen, D; Tohka, J	1

Reviews

1 review(s) available for trimipramine and sirolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

2 other study(ies) available for trimipramine and sirolimus

Article	Year
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochemical and biophysical research communications, 2004, Mar-19, Volume: 315, Issue:4 Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity	2004
In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned. International journal of molecular sciences, 2019, Oct-29, Volume: 20, Issue:21 Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Brain Injuries, Traumatic; Cell Line; Clomipramine; Coculture Techniques; Cytokines; Disease; Gene Expression; In Vitro Techniques; Ionomycin; Machine Learning; Male; Microglia; Neurons; Neuroprotection; Neuroprotective Agents; NF-E2-Related Factor 2; Nitrites; Rats; Sirolimus; Systems Biology; Transcriptome; Trimipramine; Tumor Necrosis Factor-alpha; Up-Regulation	2019

Article

Year

Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.

Biochemical and biophysical research communications, 2004, Mar-19, Volume: 315, Issue:4

Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity

2004

In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.

International journal of molecular sciences, 2019, Oct-29, Volume: 20, Issue:21

Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Brain Injuries, Traumatic; Cell Line; Clomipramine; Coculture Techniques; Cytokines; Disease; Gene Expression; In Vitro Techniques; Ionomycin; Machine Learning; Male; Microglia; Neurons; Neuroprotection; Neuroprotective Agents; NF-E2-Related Factor 2; Nitrites; Rats; Sirolimus; Systems Biology; Transcriptome; Trimipramine; Tumor Necrosis Factor-alpha; Up-Regulation

2019